Advice
The marketing authorisation for albiglutide (Eperzan) has been withdrawn.
Medicine details
- Medicine name:
- albiglutide (Eperzan)
- SMC ID:
- 1024/15
- Indication:
- Treatment of type 2 diabetes mellitus in adults to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.
- Pharmaceutical company
- GlaxoSmithKline UK Ltd
- BNF chapter
- Endocrine system
- Submission type
- Full
- Status
- Withdrawn
- Date advice published
- 11 January 2016
Additional notes
Discontinuation of albiglutide (Eperzan): On 1st July 2018, GSK discontinued the commercial sale and availability of Eperzan worldwide. Commercial supplies are no longer available in the UK.